The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Same but more information...
https://finance.yahoo.com/amphtml/news/vir-biotechnology-gsk-announce-nhs-080000896.html?__twitter_impression=true
That's alot of kit ??
https://bidstats.uk/tenders/2021/W02/742785107
(Reuters) - British drugmaker GSK and U.S.-based Vir Biotechnology will evaluate a second antibody-based treatment in patients with mild to moderate COVID-19 in an early- to mid-stage trial, the companies said on Tuesday.
The new trial, supported by England’s National Health Service, is expected to begin in the first quarter of 2021 at multiple sites across the UK, the companies said in a joint statement.
Preclinical data suggested the companies’ monoclonal antibody (mAb) has the ability to clear infected cells and the potential to enhance virus-specific T cell function, which could help treat and/or prevent infection.
This would become the second mAb from the Vir-GSK collaboration to be investigated as a potential COVID-19 treatment, with the first currently being assessed in two global late-stage studies.
“This study will be critical... as we work to understand whether the modifications we have made to this monoclonal antibody increase its potency and stimulate a T cell response to not only provide therapeutic benefits but also potentially confer a vaccine-like effect,” Vir CEO George Scangos said.
GSK and Vir had set out in October to expand a trial of their first experimental COVID-19 antibody to 1,300 patients globally after initial use by a group of volunteers did not raise any safety concerns.
mAbs mimic natural antibodies generated in the body to fight off infection and can be synthesised in the laboratory to treat diseases in patients. Current uses include treatment of some types of cancers.
Other drugmakers testing mAbs as COVID-19 treatments include Regeneron Pharmaceuticals Inc, Eli Lilly, Roche and AstraZeneca.
GlaxoSmithKline is also working on a COVID-19 vaccine with Sanofi, but last month the French company said the shot showed an insufficient immune response in clinical trial results.
sorry for the multiple links....
https://twitter.com/Antonyblood1/status/1348935552243007488?s=20
https://www.reuters.com/article/ukDomestic/idUSKBN29H0VZ?il=0
https://www.reuters.com/article/ukDomestic/idUSKBN29H0VZ?il=0
Sorry for the layout as i was working on my phone...
Good to see another British company getting a contract with the UK gov.
Bodes well for us....
Surescreen £6 million awardhttps://bidstats.uk/tenders/2021/W02/742719817
Global £3 million awardhttps://bidstats.uk/tenders/2021/W01/742457586
Good to see another British company getting a contract with the UK gov.Bodes well for us....Surescreen £6 million awardhttps://bidstats.uk/tenders/2021/W02/742719817Global £3 million awardhttps://bidstats.uk/tenders/2021/W01/742457586
https://theconversation.com/amp/why-we-need-to-test-covid-19-tests-149259?__twitter_impression=true
Watch this video from sky in September and form your own opinion .
https://news.sky.com/story/coronavirus-company-behind-15-minute-antigen-test-says-its-a-game-changer-12078934
Lee - regarding Matt...a picture paints a thousand words. Lol
Keep up the good work and good luck with your investment
Tokyo emergency: Japan shuts down capital as covid cases erupt - 9 million under lockdown
Maccad499 - not sure about that....the price has been way higher with a lot less !